• 제목/요약/키워드: small cell lung cancer

검색결과 1,119건 처리시간 0.031초

Application of machine learning and deep neural network for wave propagation in lung cancer cell

  • Xing, Lumin;Liu, Wenjian;Li, Xin;Wang, Han;Jiang, Zhiming;Wang, Lingling
    • Advances in nano research
    • /
    • 제13권3호
    • /
    • pp.297-312
    • /
    • 2022
  • Coughing and breath shortness are common symptoms of nano (small) cell lung cancer. Smoking is main factor in causing such cancers. The cancer cells form on the soft tissues of lung. Deformation behavior and wave vibration of lung affected when cancer cells exist. Therefore, in the current work, phase velocity behavior of the small cell lung cancer as a main part of the body via an exact size-dependent theory is presented. Regarding this problem, displacement fields of small cell lung cancer are obtained using first-order shear deformation theory with five parameters. Besides, the size-dependent small cell lung cancer is modeled via nonlocal stress/strain gradient theory (NSGT). An analytical method is applied for solving the governing equations of the small cell lung cancer structure. The novelty of the current study is the consideration of the five-parameter of displacement for curved panel, and porosity as well as NSGT are employed and solved using the analytical method. For more verification, the outcomes of this reports are compared with the predictions of deep neural network (DNN) with adaptive optimization method. A thorough parametric investigation is conducted on the effect of NSGT parameters, porosity and geometry on the phase velocity behavior of the small cell lung cancer structure.

A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer

  • Yang, Song
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권14호
    • /
    • pp.5963-5966
    • /
    • 2015
  • Background: This analysis was conducted to evaluate the efficacy and safety of a combination of gemcitabine and nedaplatin in treating patients with non-small cell lung cancer. Methods: Clinical studies evaluating the efficacy and safety of a combination of gemcitabine and nedaplatin with attention to response and safety for patients with non-small cell lung cancer were identified using a predefined search strategy. Pooled response rates for gemcitabine and nedaplatin were calculated. Results: In gemcitabine and nedaplatin based regimens, 4 clinical studies including 112 patients with non-small cell lung cancer were considered eligible for inclusion. The pooled analysis suggested that the pooled reponse rate was 40.2% (45/112). Main side effects included grade 3-4 neutropenia, thrombocytopenia, and anemia. Grade 3-4 nonhematological toxicity included nausea and vomiting, diarrhea, and hepatic dysfunction. There were no treatment-related deaths. Conclusion: This evidence based analysis suggests that the combination of gemcitabine and nedaplatin is associated with good response rate and accepted toxicity for treating patients with non-small cell lung cancer.

알레젠 제거 옻나무 추출물 투여로 생존기간이 연장된 편평세포폐암 환자 1례 (A Case Report of Squamous Cell Lung Cancer Patient Treated with Allergen Removed Rhus Verniciflua Stokes Extract)

  • 김은희;박소정;최원철;이수경
    • 대한암한의학회지
    • /
    • 제16권2호
    • /
    • pp.35-41
    • /
    • 2011
  • Background : Lung cancer is one of the most common malignancy in the world. Types of lung cancer are Non small cell lung cancer and small cell lung cancer. Subtypes of Non small cell lung cancer are adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Knowing the type of lung cancer is important in determining both treatment and prognosis. Recently, due to newly developed anti-cancer drugs, squamous cell carcinoma has relatively poor prognosis than non-squamous cell carcinoma. Case : We report a squamous cell lung cancer case treated with allergen removed Rhus verniciflua Stokes (aRVS) extract. The patients initially diagnosed stage squamous cell lung carcinoma, but she refused recommended operation. She initiated aRVS extract monotherapy in October. 2006. The follow up Computed tomography in March. 2007, she diagnosed stable disease of tumor response on aRVS treatment. However, this case was lost to follow up for 6 months while she was treated with tomotherapy. In October 2007, she came back to our cancer center after diagnosed stage IV metastasized lung to lung, and aRVS monotherapy was restarted. She had survived 2 years after metastasis of squamous cell lung carcinoma. Conclusion : Allergen removed Rhus verniciflua Stokes(aRVS) sucessfully prolonged overall survival of a squamous cell lung cancer patient.

옻나무추출물 위주의 한방치료로 국소 진행된 비소세포폐암 환자의 잔존 종양의 관해와 생존기간이 연장된 사례 (Case Study: Regression of a Residual Tumor and Prolongation of Overall Survival with Allergen-removed Rhus verniciflua Stokes after Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer)

  • 김경석
    • 대한한방내과학회지
    • /
    • 제36권2호
    • /
    • pp.200-206
    • /
    • 2015
  • Objectives: The purpose of this study is to report the possibility of treatment of locally advanced non-small cell lung cancer with Traditional Korean Medicine based allergen-removed Rhus verniciflua Stokes (ARVS) following chemoradiotherapy. Methods: A patient with locally advanced non-small cell lung cancer (stage IIIB) felt chest discomfort, fatigue, and anxiety after chemoradiotherapy. To prevent recurrence, he opted to receive Traditional Korean Medicine. Results: After treatment with ARVS, the size of the residual primary cancer and a metastatic lymph node decreased, without new cancerous regions. The patient has maintained good performance and has shown prolonged overall survival. Conclusions: This report suggests that ARVS may play a therapeutic role in the treatment of locally advanced non-small cell lung cancer after chemoradiotherapy. Further studies will be needed to determine the effect of ARVS on locally-advanced unresectable non-small cell lung cancer.

소세포폐암에저의 $^{18}F-FDG$ PET의 임상 이용 (Clinical Application of $^{18}F-FDG$ PET in Small Cell Lung Cancer)

  • 최준영
    • Nuclear Medicine and Molecular Imaging
    • /
    • 제42권sup1호
    • /
    • pp.29-31
    • /
    • 2008
  • This review focuses on the clinical use of $^{18}F-FDG$ PET in small cell lung cancer. For initial staging of small cell lung cancer, $^{18}F-FDG$ PET appears to be better than conventional staging methods. $^{18}F-FDG$ PET seems to be potentially useful for detecting recurrence, restaging and therapy response assessment in small cell lung cancer. However, due to small number of literatures, the role of $^{18}F-FDG$ PET in small cell lung cancer requires further investigations.

A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer

  • Li, Yang;Huang, Xin-En
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권11호
    • /
    • pp.4797-4800
    • /
    • 2015
  • Background: This analysis was conducted to evaluate the efficacy and safety of crizotinib based regimens in treating Chinese patients with EML4-ALK positive non-small-cell lung cancer. Materials and Methods: Clinical studies evaluating the efficacy and safety of crizotinib based regimens on response and safety for Chinese patients with EML4-ALK positive non-small-cell lung cancer were identified by using a predefined search strategy. Pooled response rate (RR) of treatment were calculated. Results: In crizotinib based regimens, 3 clinical studies which including 128 Chinese patients with EML4-ALK positive non-small-cell lung cancer and treated with crizotinib based regimen were considered eligible for inclusion. Pooled analysis suggested that, in all patients, the pooled RR was 59.3% (76/128) in crizotinib based regimens. ALT/AST mild visual disturbances, nausea, and vomiting were the main side effects. No treatment related death occurred in these crizotinib based treatments. Conclusions: This pooled analysis suggests that crizotinib based regimens are associated with good response rate and accepted toxicities in treating Chinese patients with EML4-ALK positive non-small-cell lung cancer.

산삼약침 혈맥주입을 시행한 비소세포성폐암 환자 2례 (Two Cases of Non-Small Cell Lung Cancer Treated with Intravenous Cultivated Wild Ginseng Pharmacopuncture)

  • 방선휘;귄기록;유화승
    • 대한약침학회지
    • /
    • 제11권2호
    • /
    • pp.13-19
    • /
    • 2008
  • Objectives To investigate the therapeutic effects of intravenous cultivated wild ginseng(Panax ginseng C.A. Meyer) pharmacopuncture(CWGP) in treating patients with non-small cell lung cancer(NSCLC). Design Prospective case series. Setting This study was conducted at the East-West Cancer Center of Dunsan Oriental Hospital, Daejeon University. Patients Two non-small cell lung cancer patients. Intervention Two non-small cell lung cancer patients were injected CWGP(20mL/day) mixed with 0.9% normal saline(100mL) intravenously. Each patient received a total of 16 and 9 cycles, respectively. One cycle is composed of 14 days. Outcome Measures The effect of intravenous CWGP was measured by scanning with computed tomography(CT) after every 2 cycle and Positron emission tomography- computed tomography(PET/CT) after every 6 cycles. Response and progression was evaluated using the Response Evaluation Criteria in Solid Tumors(RECIST) Committee classification of complete response(CR), partial response(PR), progressive disease(PD) and stable disease(SD). Results They were treated with intravenous CWGP for 8 and 5 months respectively. time later, each tumor remains stable disease(SD). Conclusion These cases may give us a possibility that intravenous CWGP offers potential benefits for non-small cell lung cancer patients.

Irinotecan as a Second-line Chemotherapy for Small Cell Lung Cancer: a Systemic Analysis

  • Zhang, Ming-Qian;Lin, Xin;Li, Yan;Lu, Shuang
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권5호
    • /
    • pp.1993-1995
    • /
    • 2015
  • Purpose: This analysis was conducted to evaluate the efficacy and safety of irinotecan based regimens as second-line chemotherapy in treating patients with small cell lung cancer. Methods: Clinical studies evaluating the efficacy and safety of irinotecan based regimens as second-line chemotherapy for patients with small cell lung cancer were identified using a predefined search strategy. Pooled response rates (RRs) of treatment were calculated. Results: In irinotecan based regimens as second-line chemotherapy, 4 clinical studies which including 155 patients with small cell lung cancer were considered eligible for inclusion. In all chemotherapy consisted of irinotecan with or without nedaplatin. Pooled analysis suggested that, in all patients, the pooled RR was 27.1% (42/155) in irinotecan based regimens. Nausea, vomiting, diarrhea and myelosuppression were the main side effects. No grade III or IV renal or liver toxicity was observed. No treatment related death occurred with the irinotecan based treatments. Conclusion: This systemic analysis suggests that irinotecan based regimens as second-line chemotherapy are associated with mild response rate and acceptable toxicity for patients with small cell lung cancer.

Season of Diagnosis and Survival of Advanced Lung Cancer Cases - Any Correlation?

  • Oguz, Arzu;Unal, Dilek;Kurtul, Neslihan;Aykas, Fatma;Mutlu, Hasan;Karagoz, Hatice;Cetinkaya, Ali
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권7호
    • /
    • pp.4325-4328
    • /
    • 2013
  • Introduction: The influence of season at diagnosis on cancer survival has been an intriguing issue for many years. Most studies have shown a possible correlation in between the seasonality and some cancer type survival. With short expected survival, lung cancer is an arena that still is in need of new prognostic factors and models. We aimed to investigate the effect of season of diagnosis on 3 months, 1 and 2 years survival rates and overall survival of non small cell lung cancer patients. Materials and Methods: The files of non small cell lung cancer patients that were stages IIIB and IV at diagnosis were reviewed retrospectively. According to diagnosis date, the patients were grouped into 4 season groups, autumn, winter, spring and summer. Results: A total of 279 advanced non small cell lung cancer patients' files were reviewed. Median overall survival was 15 months in the entire population. Overall 3 months, 1 and 2 years survival rates were 91.0%, 58.2% and 31.2% respectively. The season of diagnosis was significantly correlated with 3 months survival rates, being diagnosed in spring being associated with better survival. Also the season was significantly correlated with T stage of the disease. For 1 and 2 years survival rates and overall survival, the season of diagnosis was not significantly correlated. There was no correlation detected between season and overall survivals according to histological subtypes of non small cell lung cancer. Conclusion: As a new finding in advanced non small cell lung cancer patients, it can be concluded that being diagnosed in spring can be a favorable prognostic factor for short term survival.

Successful Treatment of Pleural Effusion in Small Cell Lung Cancer Patient with Gunreyngtang-gagambang

  • Yun, Hen-Ja
    • 대한한의학회지
    • /
    • 제32권6호
    • /
    • pp.117-121
    • /
    • 2011
  • Objectives: We report one patient with pleural effusion and effusion-related symptoms in small cell lung cancer (SCLC) successfully treated with Gunreyngtang-gagambang. Methods: Gunreyngtang-gagambang was administered at 30 minutes after mealtime, three times a day, for two months. Except for herbal medicine, the patient did not take any treatment including pharmaceutical or non pharmaceutical for effusion. Result: Two months later, the symptoms and the pleural effusion had disappeared from chest X-ray. Conclusion: Gunreyngtang-gagambang was effective for treatment of malignant pleural effusion due to small cell lung cancer.